The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients

NCT01141777 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2011-01-04

No results posted yet for this study

Summary

Spirulina, a widely used food supplement, improves the lipid profile and glycemic control in people living with diabetes, suggesting that it could have some effects on insulin sensitivity. Since HIV-infected patients develop metabolic abnormalities due to the virus and/or to antiretroviral (ARV) drugs, the investigators therefore proposed to evaluate the effect that spirulina can have on HIV/HAART-associated insulin resistance

Conditions

Interventions

DIETARY_SUPPLEMENT

Spirulina platensis

Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance

DIETARY_SUPPLEMENT

Soya bean

Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.

Sponsors & Collaborators

  • University of Yaounde

    collaborator OTHER
  • Antenna Technologies

    collaborator UNKNOWN
  • Yaounde Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Pr Jean Claude Mbanya, MD, PhD · International diabetes federation/ Director, National Obesity Centre, Yaounde Central Hospital, Cameroon

  • Dr Sobngwi Eugene, MD, PhD · Consultant Endocrinologist, National Obesity Centre/ Senior Lecturer, University of Yaounde 1, Cameroon and Newcastle University, UK

  • Dr Marcel Azabji Kenfack, MD · Dep. of Physiologie, Faculty of Medicine and Biomedical Sciences University Yaoundé I, Cameroon

  • Dr Gabriel Loni Ekali, MD · National Obesity Centre, Yaounde Central Hospital, Cameroon

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Cameroon

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141777 on ClinicalTrials.gov